Market Trends of AI-Powered Clinical Decision Support Industry
The Medical Diagnosis Segment is Expected to Witness Significant Growth During the Forecast Period
AI-powered clinical decision support systems in medical diagnosis use artificial intelligence technologies to assist healthcare professionals in identifying, diagnosing, and managing medical conditions. These systems aim to enhance diagnostic accuracy and efficiency by analyzing vast amounts of medical data.
Factors such as the rising burden of chronic and infectious diseases among the population propelling the demand for early diagnosis and advanced treatments, increasing demand for personalized medicines, and technological advancements are expected to boost the segment's growth during the forecast period.
The rising burden of chronic diseases such as cancer among the population propels the need for early diagnosis and therapeutics, which is anticipated to propel the segment's growth. For instance, according to the data updated by the Spanish Network of Cancer Registries (REDECAN) in January 2024, approximately 286,664 new cancer cases are expected to be diagnosed in Spain in 2024 compared to 279,260 new cases of cancer diagnosed in Spain in 2023. AI-powered clinical decision support is increasingly being utilized in cancer care to enhance diagnosis, treatment, planning, and patient management, hence anticipated to drive the segment's growth during the forecast period.
Artificial intelligence (AI) has found extensive applications across various medical domains, including image diagnosis, pathological classification, treatment selection, and prognosis analysis. Numerous studies have evaluated the efficacy of AI-driven Clinical Decision Support (CDS) systems in diagnosing cancer in patients. For instance, a January 2023 article in the International Journal of Medical Sciences highlighted that AI-based CDS systems play a pivotal role in suggesting tumor treatments, particularly in hospitals with limited access to expert resources.
Similarly, an article published in Infection and Drug Resistance in July 2024 highlighted the capabilities of AI-CDSS in enhancing clinical decision-making. Specifically, AI-CDSS provides clinicians with real-time, data-driven insights, especially in treating infections from carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. The system rapidly decodes intricate diagnostic data, suggests tailored treatment plans, and forecasts potential resistance trends. This streamlines diagnostics and promotes a focused approach to antibiotic therapy. Thus, the introduction of AI-CDSS underscores the commitment to harnessing cutting-edge technology to combat antibiotic resistance, marking a significant step in improving clinical outcomes and promoting responsible antibiotic use.
Therefore, the high burden of cancer, coupled with the increasing utilization of AI-powered CDSS in the diagnosis of various diseases, the segment is anticipated to witness significant growth during the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
Factors such as the rising prevalence of diseases, increasing incidents of medical errors, the growing complexity of healthcare in the country, government initiatives to improve patient outcomes, technological advancements, and focus on cost-effectiveness are expected to boost the market's growth.
The increasing burden of chronic diseases among the population is the key factor driving the market's growth. For instance, according to 2024 updated data published by the International Diabetes Federation, about 17 million people are expected to suffer from diabetes in Mexico, and this number is projected to reach 21 million by 2045. Hence, AI-powered CDSS can assist healthcare professionals in managing these complex conditions by providing decision support for diagnosis, treatment options, medication management, and preventive care, contributing to better outcomes for patients with chronic diseases.
Furthermore, the development of a technologically advanced clinical decision support system for accelerating disease diagnosis is expected to surge the market growth over the forecast period. For instance, in July 2024, DIGITAL, Canada's Global Innovation Cluster for digital technologies, made its largest investment in collaboration with pioneering Canadian health tech companies and researchers, aiming to propel the development and implementation of AI-driven technologies. These advancements are designed to bolster support for healthcare providers and improve patient outcomes. Through its investment in the Health Compass II project, DIGITAL is set to roll out a cutting-edge suite of four AI-driven modules. These modules are crafted to boost patient engagement, alleviate administrative burnout, aid healthcare professionals in documentation, and refine clinical decision-making.
Similarly, in January 2023, VisualDx received a grant from the Bill & Melinda Gates Foundation to develop diagnostic and surveillance tools to help medical providers improve treatment decisions and outcomes in underserved areas. VisualDx expanded equitable access to its clinical decision support, artificial intelligence (AI), and machine learning (ML) tools to provide guidance, specialist knowledge, and education for providers in low-resource settings.
Moreover, increasing government initiatives to integrate AI-driven clinical decision support systems into medical device regulations are expected to boost their adoption in medical diagnostics and treatment strategies. For instance, in September 2022, the Food and Drug Administration issued new guidance indicating that certain AI tools warrant regulation as medical devices, reinforcing the agency's oversight of clinical decision support (CDS) software. This guidance enumerates specific AI tools, such as those predicting sepsis, predicting future heart failure, and detecting potential opioid addiction, that should be classified and regulated as medical devices.
Therefore, owing to the high burden of cancer and diabetes, technological advancement in CDS systems, and government initiatives, the studied market is expected to grow during the forecast period.
